Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Number of Exercisable Options

Number of Exercisable Options at other companies

Immunovant, Inc. logo
Immunovant, Inc.IMVT
5M-45.1%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%
Enterprise value$1.32B+288%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's number of exercisable options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's number of exercisable options?
Bicara Therapeutics (BCAX) reported number of exercisable options of 3.3M in Q1 2026.
How has Bicara Therapeutics's number of exercisable options changed year-over-year?
Bicara Therapeutics's number of exercisable options increased by 87.1% year-over-year, from 1.8M to 3.3M.
What does number of exercisable options mean?
The number of share-based payment options that have met all vesting requirements and are currently eligible for exercise by the holders. This represents the portion of the equity incentive pool that could be converted into common stock immediately. It is a critical component for calculating fully diluted share counts.